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conducted among general practice patients who were
deﬁned as likely to have obstructive airways disease on
the basis of a previous postal respiratory questionnaire.
The six-item severity questionnaire was based on the
GINA guidelines and considered symptom frequency and 
intensity. Individuals were categorised into one of four
severity groups. Healthcare utilisation events and cost of
care (over six months) for the four groups were com-
pared. RESULTS: Disease was classiﬁed as intermittent in
52.9%, mild persistent in 27.2%, moderate persistent in
12.9% and severe persistent in 7.1%. The six items 
of the severity questionnaire were strongly correlated
(Spearman’s rho 0.56–0.80, p < 0.001 throughout), 
suggesting measurement of a single construct. Severity
classiﬁcation using the questionnaire was signiﬁcantly
correlated with healthcare utilisation and cost. In general,
those categorised as having the most severe disease had
at least double the healthcare utilisation of those with
least severe disease, with mean total cost over 6 months
increasing from £428.55 (least severe) to £1,431.50 (most
severe) (p < 0.001 for correlation). CONCLUSIONS:
This short postal questionnaire will provide a useful 
categorisation of obstructive airways disease severity in
large scale epidemiological studies.
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OBJECTIVES: The main objective of present study was
to evaluate the discriminatory ability of the HRQOL 
in relationship to severity degree in asthma patients.
METHODS: Cross-sectional descriptive study carried out
in a semirural county of 110.000 inhabitants. Patients
were included in stable asthma phase, and classiﬁed into
three groups: mild, moderate, and severe. Assessment
included spirometry, sociodemographic, clinical data
(morbidity and use of health-services), and two HRQOL
questionnaires: one generic, the Nottingham Health
Proﬁle (NHP), and one speciﬁc, the St. George’s 
Respiratory Questionnaire (SGRQ). HRQOL scores were
standardized by age and gender according to Spanish
population norms. RESULTS: Out of 385 patients with
asthma, 52 were excluded because different reasons, and
333 adult patients were included with a mean age of 42
years (64% were females). Patients were classiﬁed accord-
ing to asthma severity degree: mild, 140 patients (42%),
moderate, 116 patients (35%), and severe, 77 patients
(23%). Median time of evolution of asthma was 8 years,
and most of patients (80.1%) had less than 3 asthma
attacks per year. NHP mean (SD) standardized score was
0.20 (1.21) for mild patients, 0.68 (1.43) moderate, and
1.21 (1.57) severe. SGRQ mean standardized score (SD)
was 2.75 (2.11) for mild patients, 3.61 (2.31) moderate,
and 4.17 (2.44) severe. Although patients with mild
asthma had low impaired FEV1, and NHP scores close
to that of general population, they showed substantial
effects on HRQOL using the speciﬁc instrument, the
SGRQ. CONCLUSIONS: Both HRQOL instruments are
associated to asthma severity degree but discriminatory
ability was higher for the disease-speciﬁc instrument. In
addition, SGRQ seems to be more useful than NHP and
traditional clinical measures identifying the mild severity
degree impact.
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OBJECTIVE: To evaluate clinical ﬁgures, quality of life
and costs of moderate or severe asthma patients in France
METHODS: A cross sectional study was carried out in a
sample of French patients included by allergologists.
Patients presenting moderate or severe asthma using
NHBLI criteria were included. Clinical information and
Quality of Life (AQLQ) were collected at the day of the
visit. Resource utilization was collected retrospectively
except for drug treatments that were collected prospec-
tively. Statistical analyses compare patients according to
their severity of asthma and level of disease control and
attempt to highlight risk factors for hospitalisations and
asthma control. Costs were valued according to French
recommendations. RESULTS: 211 patients were included
and analysed of whom 32.1% of severe and 67.9% of
moderate asthma. Controlled patients were 35.1% and
64.9% of the patients were not controlled (at least one
acute episode during the previous year). There are statis-
tical differences in clinical ﬁgures, Quality of Life and
resources utilization between controlled and uncontrolled
patients, as well as, on uncontrolled patients, between
those hospitalized and those not. Annual cost of uncon-
trolled hospitalised patients is three times higher than
costs of ambulatory patients uncontrolled and 4 times
higher than controlled patients. Patient’s hospitalisations
can be predicted by the level of night-time symptoms and
level of quick relief treatment as well as asthma control
can be predicted by the level and frequency of exacerba-
tions and the level of severity assessed by physicians.
CONCLUSION: Uncontrolled asthma is responsible for
high costs. There is a need for a treatment able to better
control asthma, to increase Quality of Life of the patients
and decrease directs costs.
